Financial Data and Key Metrics Changes - Revenue reached RMB 21.8 billion, a 16.7% increase from 2024, with a sequential growth of about 18% in the second half compared to the first half [25][26] - Adjusted net profit increased by 22% year-over-year to RMB 6.6 billion, with a margin expansion of 130 basis points to 30.2% [32][34] - Adjusted EBITDA rose by 22.8% to RMB 9.8 billion, with an adjusted EBITDA margin of 45.1%, one of the highest in the global CDMO industry [32][34] Business Line Data and Key Metrics Changes - Research and discovery services saw a doubling of upfront payments to $115 million, with potential milestone income streams exceeding $4 billion [27] - Development revenue grew by approximately 32% year-over-year, driven by 209 new projects, with 186 in the pre-IND space [28] - Manufacturing revenue from late-phase and commercial projects grew over 26% year-over-year, now representing over 43% of the total portfolio [29] Market Data and Key Metrics Changes - The U.S. accounted for 58% of revenue, growing over 18%, while Europe contributed 23% with nearly 17% growth [16] - Japan and Korea experienced significant growth of almost 70%, now representing 6.5% of total revenue [16][17] - China saw a slight decline in revenue, but adjusting for out-licensing deals shows nearly flat year-over-year growth [17][18] Company Strategy and Development Direction - The company emphasizes a unique CRDMO business model, focusing on bi-specifics, ADCs, and traditional mAbs to drive sustainable high growth [3][4] - The strategy includes expanding capabilities in complex modalities, which are expected to enhance market share due to their challenging nature [20][21] - Continuous investment in technology and capacity expansion in key markets like the U.S. and Singapore is planned to support future growth [59][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges geopolitical uncertainties but remains optimistic about sustained growth driven by a strong project funnel and client trust [8][14] - The company expects to continue delivering high growth, with a focus on maintaining a sticky project funnel despite external challenges [14][19] - Future revenue growth is anticipated from the successful execution of projects and the introduction of new technologies [58][64] Other Important Information - The company reported a significant increase in gross profit, reaching over RMB 10 billion, with a 31% increase in gross profit margin [30][37] - The company has a strong balance sheet with RMB 15.7 billion in cash, supporting accelerated global growth [41][43] - The company is committed to continuous improvement through the WuXi Business System, achieving a 150 basis points improvement in margin [70] Q&A Session Summary Question: What are the key drivers of revenue growth? - Revenue growth was driven by R&D services, particularly in bispecifics and ADCs, with a strong pipeline of new deals expected to continue into 2026 [27][28] Question: How does the company plan to manage geopolitical risks? - The company acknowledges the geopolitical noise but emphasizes the stickiness of its project funnel and strong client relationships as mitigative factors [8][14] Question: What is the outlook for the manufacturing segment? - The manufacturing segment is expected to grow significantly, with a focus on late-phase projects and commercial manufacturing, which have shown strong revenue growth [29][30]

Investment Rating - The report does not explicitly state an investment rating for the gastric cancer antibody therapeutics industry Core Insights - The Chinese gastric cancer antibody drug industry is evolving from a "single treatment paradigm" to a "layered, combinatorial, and platform-based" approach, with clinical decisions increasingly relying on key biomarkers for stratification [2] - The industry is characterized by a multi-technical route landscape, where traditional monoclonal antibodies remain foundational, while new forms like bispecific antibodies and antibody-drug conjugates (ADCs) enrich the product spectrum [2][3] - The core of industry evolution lies in enhancing treatment efficiency through clinical evidence and stratified pathways, while reducing R&D and delivery uncertainties via technological platforms and industrial capabilities [3] Summary by Sections Overview of Gastric Cancer in China - Gastric cancer is a prevalent and deadly disease, primarily affecting middle-aged and elderly patients, with a significant proportion diagnosed at advanced stages, leading to prolonged treatment periods and increased management needs [13][27] - The disease burden is substantial, with 358,672 new cases and 260,372 deaths reported in 2024, ranking gastric cancer as the fifth most common and third deadliest cancer in China [15] Industry Value Chain and Supply System - The industry value chain is driven by molecular profiling for targeted therapy and technological platform iterations, encompassing R&D registration, CMC scaling, and quality system construction [35] - Upstream, the localization of key raw materials and tools is driving down costs, with a reported 40%-50% decrease in the price of Protein A resin, which is crucial for antibody purification [43][45] - Midstream, the integration of quality systems and digital analytics is enhancing efficiency and reducing product deviation rates [39][43] - Downstream, the establishment of diagnostic closed loops and reimbursement access is facilitating the volume ramp-up of antibody drugs [39] Competitive Landscape - The competition in the gastric cancer antibody drug market is shifting from "efficacy comparison" to "population stratification," where target positivity rates determine market potential and volume growth [20] - The report highlights that the PD-1/PD-L1 inhibitors have the highest treatment maturity, serving as a scalable foundation for first-line combination therapies, while HER2 and CLDN18.2 require precise stratification for stable market penetration [20][41] Future Growth Drivers - The diversification of technology routes is expected to enhance coverage and accessibility in the gastric cancer antibody therapeutics market [41] - The report emphasizes the importance of clinical evidence quality, platform capabilities, commercialization execution, and stable supply in determining competitive advantages among companies [3]

InnoCare Pharma 2025 Annual Results Earnings Call Stock Code: 09969.HK, 688428.SH March 25, 2026 1 Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the "Company") or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection ...

Investment Rating - The report does not explicitly state an investment rating for the gastric cancer antibody drug industry Core Insights - The gastric cancer antibody drug industry is transitioning from a "single treatment paradigm" to a "layered, combinatorial, and platform-based" approach, emphasizing the importance of biomarker identification and the integration of various treatment modalities [2][3] - The industry's evolution is driven by clinical evidence and stratified pathways to enhance treatment efficiency, while technological platforms and industrial capabilities reduce uncertainties in research and delivery [3] - The competitive landscape is shifting towards a focus on "evidence quality, platform capabilities, commercialization execution, and stable supply," leading to a higher quality of industry development and resource concentration towards leading platforms [3] Summary by Sections Overview of Gastric Cancer in China - Gastric cancer is a prevalent and deadly disease in China, with a significant proportion of patients diagnosed at advanced stages, leading to increased treatment duration and management needs [13][27] - The disease burden includes approximately 358,672 new cases and 260,372 deaths annually, ranking gastric cancer as the fifth most common and third deadliest cancer in China [15] Industry Value Chain and Supply System - The industry value chain consists of upstream target discovery and antibody engineering, midstream drug development, and downstream patient accessibility and management through hospital channels [32][33] - Upstream, the localization of key raw materials and technologies is driving down costs, with a notable 40-50% decrease in the price of Protein A resin, which is crucial for antibody purification [43][45] - Midstream, the integration of quality systems and digital analytics is enhancing the efficiency and reliability of drug development processes [39][43] - Downstream, the establishment of diagnostic closed loops and improved reimbursement access are critical for increasing the volume of antibody drug prescriptions [39][41] Competitive Landscape - The competitive dynamics are shifting from a focus on individual drug efficacy to population stratification, where target positivity rates dictate market potential and prescription volume [20][41] - The report highlights the importance of dual-specific antibodies and antibody-drug conjugates (ADCs) in enhancing treatment efficacy and addressing patient heterogeneity [5][38] - The commercialization process is characterized by a rapid feedback loop from evidence generation to market access, with core cities often leading the adoption of new therapies [5][39] Future Growth Drivers - The future growth of the gastric cancer antibody drug market is expected to be driven by diversified technology routes that improve treatment coverage and accessibility [41][42] - The report emphasizes the need for continuous innovation in treatment modalities and the importance of regulatory support to facilitate the development and market entry of new therapies [29][39]

Core Viewpoint - BeiGene is projected to achieve a revenue of $5.343 billion in 2025, representing a year-on-year growth of 40.2%. The company is also expected to report a net profit of $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1]. Financial Performance - Revenue for 2025 is estimated at $5.343 billion, indicating a growth rate of 40.2% compared to the previous year [1]. - The net profit is forecasted to be $287 million, contrasting with a net loss of $645 million in the same quarter of the previous year [1].

Scaled CRDMO Platform and Three Key Modalities Delivering Sustained High Growth 2025 Annual Results Operation & Business Updates 01 03 05 02 04 06 2025 Annual Results WBS (WuXi Bio Business System) & ESG as Key Components of Business Strategy FY2025 Financials Review Advanced Technology Platforms – Cornerstone of Future Success Summary & Outlook 01 2025 Annual Results March 2026 Stock Code: 2269.HK Forward-Looking Statements This presentation may contain certain "forward-looking statements" which are not hi ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 （於香港註冊成立的有限公司） （股份代號：3681） 自願公告 頂線結果 SM17中國給藥途徑轉換1期橋接研究 健康參與者接受皮下注射製劑給藥後達成： 茲提述本公司日期為二零二二年二月十六日、二零二二年三月十四日、二零二二 年六月十五日、二零二三年五月二十二日、二零二三年六月十二日、二零二三年 八月十四日、二零二三年九月十一日、二零二三年十一月二十七日、二零二四年 六月十一日、二零二五年四月七日、二零二五年十月十四日、二零二五年十二月 十一日及二零二六年二月二十四日的公告，內容有關本集團主要產品之一SM17的 最新研發進展。 本公司董事會（「董事會」）欣然宣佈SM17在中國進行的給藥途徑轉換1期橋接研究 取得良好頂線結果。首組健康參與者於二零二五年 ...

Investment Rating - The report maintains a "Buy" rating for Keren Biotechnology (06990), indicating a positive outlook for the company as it is positioned to become a leading global ADC enterprise due to its differentiated ADC pipeline, strong R&D foundation, and deep collaboration with Merck [1] Core Insights - Keren Biotechnology's core product, sac-TMT (Lukangshatuo), is identified as the main growth driver for the company, with significant clinical advantages demonstrated in key studies [1] - The product has shown a progression-free survival (PFS) of 7.9 months compared to 2.8 months for chemotherapy (HR=0.23) and an overall survival (OS) of 20 months compared to 11.2 months for chemotherapy (HR=0.45), indicating its competitive edge in the market [1] - The company expects substantial sales growth for sac-TMT in 2026, especially after its inclusion in the national medical insurance directory, with projections indicating that this product will contribute over 80% of revenue [1] Clinical Development - 2026 is highlighted as a critical year for Keren Biotechnology, with a focus on the ongoing Phase III clinical trials of sac-TMT combined with Pembrolizumab (Keytruda) for first-line treatment of non-small cell lung cancer, with key data expected to be released throughout the year [2] - The company has already achieved primary endpoints in its Phase III study for PD-L1 positive non-small cell lung cancer, reinforcing confidence in the clinical value of the ADC + IO combination [2] - Keren Biotechnology is also advancing other ADC pipelines and combinations with immunotherapies and small molecule targeted therapies to expand indications [2] Competitive Advantages and Innovation - Keren Biotechnology has established collaborations with Merck for several ADC projects, including SKB410 and SKB571, which have shown significant progress in a competitive landscape [3] - The company is exploring diverse technological pathways, including RDC and dual payload ADCs, with several innovative products already in clinical stages [3] - Notable projects include SKB107 for advanced solid tumors, SKB103 as a dual-target ADC, and SKB565, which introduces a new concept of dual delivery for enhanced anti-tumor effects [3] Long-term Growth Potential - Keren Biotechnology is expected to continue unlocking pipeline value and driving long-term growth by leveraging its ADC technology advantages and global collaborations with international pharmaceutical companies like Merck [4]

Core Viewpoint - The article discusses the significant progress of Xianweida Biotech, which has transitioned from a research-focused company to a commercial entity with its core product, Enoglutide injection, receiving approvals for both type 2 diabetes and long-term weight management in overweight or obese adults [4][5]. Group 1: Product Development and Approval - Xianweida's core product, Enoglutide, was approved for type 2 diabetes in January and for long-term weight management in March, marking its first commercial product [5]. - The product is characterized as a cAMP biased GLP-1 receptor agonist, aiming to balance efficacy and tolerability by reducing receptor desensitization and adverse reactions compared to traditional GLP-1 drugs [5]. - Clinical data shows a 15.1% weight loss effect in overweight or obese individuals and a 2.43% reduction in HbA1c for diabetes treatment, indicating competitive results in both areas [5]. Group 2: Commercialization and Partnerships - Pfizer's partnership with Xianweida, announced on February 24, grants Pfizer exclusive commercialization rights for Enoglutide in mainland China, with a total deal value of up to $495 million [6]. - This collaboration not only provides financial support but also addresses Xianweida's commercialization capabilities, leveraging Pfizer's established network for faster market entry [6]. - The IPO submission is not merely for financing but is also a strategic move to enter the market with an approved product and a partnership with a multinational pharmaceutical company [6]. Group 3: Financial Performance and Future Outlook - Xianweida remains in a pre-commercialization phase, having incurred losses over the past two years, with revenue not yet reflecting product sales contributions [7]. - The upcoming IPO aims to secure funding for expanding indications for Enoglutide, advancing oral pipeline projects, enhancing production capacity, and supporting overall operational funding [7]. - The company has successfully introduced a differentiated product to the market and partnered with Pfizer, but it now faces challenges in scaling production, market access, and managing payment systems [7]. Group 4: Shift in Focus - The second IPO submission marks a shift from a purely technical narrative to a focus on market realization, with the biased GLP-1 as a key differentiator and Pfizer's collaboration as a crucial support [8]. - The market will be watching not only for the technical differentiation but also for the actual sales, market share, and sustained growth of Xianweida's products [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved total revenue of 2.058 billion yuan in 2025, representing a year-on-year increase of 6.5%. The revenue from drug sales surged by 949.8% to 543 million yuan, primarily due to the approval of new indications for key products [8] - The commercialization of the core product, Lukanosatuzumab (佳泰莱®), is progressing smoothly, with coverage across 30 provinces and over 2,000 hospitals in China. Several new indications have been approved for inclusion in the national medical insurance directory [8] - The company has a robust pipeline with multiple clinical trials ongoing, including four approved indications for Lukanosatuzumab and several others in advanced stages of clinical development [8] - The financial outlook remains positive, with projected revenues of 3.56 billion yuan in 2026, 5.89 billion yuan in 2027, and 7.66 billion yuan in 2028, indicating significant growth potential [8] Financial Summary - Total revenue is forecasted to reach 2.058 billion yuan in 2025, with a year-on-year growth of 6.46% [9] - The net profit attributable to the parent company is expected to improve significantly, with projections of a loss of 112.49 million yuan in 2026 turning into a profit of 649.80 million yuan by 2027 [9] - The company’s cash and financial assets exceeded 4.542 billion yuan by the end of 2025, reflecting a 48% increase, indicating strong liquidity [8] - The gross margin is expected to improve to 82.21% by 2027, showcasing enhanced operational efficiency [9]